In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate.
The purpose of this study was to develop Pluronic F127 (PF127) based formulations of timolol maleate (TM) aimed at enhancing its ocular bioavailability. The effect of isotonicity agents and PF127 concentrations on the rheological properties of the prepared formulations was examined. In an attempt to reduce the concentration of PF127 without compromising the in situ gelling capabilities, various viscosity enhancing agents were added to PF127 solution containing 0.5% TM. The viscosity and the ability of PF127 gels to deliver TM, in vitro, in absence and presence of various viscosity enhancing agents were also evaluated. At the used concentration, some of the examined isotonicity agents had effect on the viscosity of TM gel. However, the viscosity of gel increased as the PF127 concentrations increased. The viscosity of formulations containing thickening agents was in the order of PF-MC 3%>PF-HPMC 2%>PF-CMC 2.5%>PF127 15%. The slowest drug release was obtained from 15% PF127 formulations containing 3% methylcellulose. In vivo study showed that the ocular bioavailability of TM, measured in albino rabbits, increased by 2.5 and 2.4 fold for 25% PF127 gel formulation and 15% PF127 containing 3% methylcellulose, respectively, compared with 0.5% TM aqueous solution.
El-Kamel
A H
AH
Department of Pharmaceutics, Faculty of Pharmacy, King Saud University, Women Students-Medical Studies and Science Sections, PO Box 22452, 11495, Riyadh, Saudi Arabia. amalelkamel@yahoo.com
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000465:Algorithms; D000818:Animals; D001082:Aqueous Humor / Q000737:chemistry / Q000378:metabolism; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D016503:Drug Delivery Systems; D005079:Excipients; D007552:Isotonic Solutions; D009883:Ophthalmic Solutions; D020442:Poloxamer; D011817:Rabbits; D013056:Spectrophotometry, Ultraviolet; D013999:Timolol / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014783:Viscosity
D000319:Adrenergic beta-Antagonists; D005079:Excipients; D007552:Isotonic Solutions; D009883:Ophthalmic Solutions; D020442:Poloxamer; D013999:Timolol